Cutaneous Lupus Erythematosus Cle Pipeline Insight
DelveInsight’s, “Cutaneous Lupus Erythematosus (CLE) – Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cutaneous Lupus Erythematosus (CLE) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cutaneous Lupus Erythematosus (CLE) Understanding
Cutaneous Lupus Erythematosus (CLE): Overview
Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are due to loss of normal immune tolerance and are pathogenic. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions. There can be some overlap:
- LE-specific cutaneous LE has been classified as acute, subacute, intermittent and chronic. Lesions may be localised or generalised. In LE-specific cutaneous LE, lesions are often induced by exposure to sunlight.
- LE-nonspecific cutaneous LE may relate to systemic LE or another autoimmune disease.
A skin biopsy may be diagnostic, showing a lichenoid tissue reaction and features specific to the kind of cutaneous LE. Direct immunofluorescence tests may show positive antibody deposition along the basement membrane (lupus band test).
Treatment may vary depending upon type of Cutaneous Lupus Erythematosus (CLE): The aim of treatment for cutaneous LE is to prevent flares, improve appearance and to prevent scarring.
- Potent or ultrapotent topical steroids are applied to chronic discoid LE plaques.
- Calcineurin inhibitors, pimecrolimus cream or tacrolimus ointment can be used instead of topical steroids.
- Intralesional corticosteroid can be injected into small lesions resistant to topical therapy.
- Topical retinoids, calcipotriol and imiquimod have also been reported to be helpful in a few patients.
- Cosmetic camouflage may be used to disguise unsightly plaques.
Treatment for cutaneous and systemic LE may include:
- Antimalarials especially hydroxychloroquine
- Immune modulators such as methotrexate, mycophenolate, dapsone, ciclosporin
- Retinoids, ie acitretin, isotretinoin
- Systemic corticosteroids
- If sun protection is strict, vitamin D supplementation.
- The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous Lupus Erythematosus (CLE) R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous Lupus Erythematosus (CLE).
- In May 2020, Viela Bio announced positive interim phase Ib data from a study with VIB7734, its novel anti-ILT7 therapy, in patients with Cutaneous Lupus Erythematosus (CLE) (CLE).
- In July 2019, Gilead Sciences and Galapagos stated that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.
- In May 2020, Hoth Therapeutics announced it has completed a strategic investment in Zylö Therapeutics.
Cutaneous Lupus Erythematosus (CLE) Emerging Drugs Chapters
This segment of the Cutaneous Lupus Erythematosus (CLE) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cutaneous Lupus Erythematosus (CLE) Emerging Drugs
Filgotinib: Galapagos/Gilead Sciences
Filgotinib (GLPG0634/GS-6034) is a potent and selective inhibitor of JAK1,7 which is currently under investigation for the treatment Cutaneous Lupus Erythematosus (CLE). It is currently in phase II stage of development.
VIB7734: Viela Bio.
VIB7734 potentially represents a novel treatment for autoimmune diseases caused by the overproduction of type I interferons and other cytokines secreted by a type of dendritic cell called pDCs. VIB7734 is designed to target and bind to ILT7, a cell surface molecule specific to pDCs, leading to their depletion. The benefits are multifold as this depletion may also decrease other inflammatory cytokines such as TNF-a and IL-6, which are critical to the pathogenesis of a number of autoimmune diseases. Viela Bio have completed a phase Ia single-ascending dose trial in patients with various autoimmune diseases including Cutaneous Lupus Erythematosus (CLE) (CLE).
HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
Hoth has entered a partnership agreement with Zylö Therapeutics Inc to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE) (CLE). HT-005 Z-Pods includes a novel topical delivery matrix (Z-Pods) loaded with an endogenous ligand with suspected immune-modulating action. Z-Pods use patented xerogel-derived nanoparticles for sustained and controlled topical delivery of active pharmaceutical ingredients. The HT-005 Z-Pods™ product is currently in the early preclinical stage of development.
Further product details are provided in the report……..
Cutaneous Lupus Erythematosus (CLE): Therapeutic Assessment
This segment of the report provides insights about the different Cutaneous Lupus Erythematosus (CLE) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cutaneous Lupus Erythematosus (CLE)
There are approx. 15+ key companies which are developing the therapies for Cutaneous Lupus Erythematosus (CLE). The companies which have their Cutaneous Lupus Erythematosus (CLE) drug candidates in the most advanced stage, i.e. phase II include Galapagos/Gilead Sciences and others
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Cutaneous Lupus Erythematosus (CLE) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cutaneous Lupus Erythematosus (CLE): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous Lupus Erythematosus (CLE) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous Lupus Erythematosus (CLE) drugs.
Cutaneous Lupus Erythematosus (CLE) Report Insights
- Cutaneous Lupus Erythematosus (CLE) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cutaneous Lupus Erythematosus (CLE) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cutaneous Lupus Erythematosus (CLE) drugs?
- How many Cutaneous Lupus Erythematosus (CLE) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous Lupus Erythematosus (CLE)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cutaneous Lupus Erythematosus (CLE) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cutaneous Lupus Erythematosus (CLE) and their status?
- What are the key designations that have been granted to the emerging drugs?